PathoVax

PathoVax LLC is a biotechnology company focused on developing a broadly preventive human papillomavirus (HPV) vaccine. Building on foundational technology developed at Johns Hopkins University, the company is advancing RGVaxTM, the world’s first comprehensive HPV vaccine designed to target all clinically relevant HPVs.